PRPF4B

Across TCGA pan-cancer cohorts, PRPF4B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PRPF4B data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PRPF4B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRPF4B expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

HNSC, LSCC, and LUAD are the cancer types where PRPF4B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.361	0.895	.007	41	view →
LSCC	OS	Tertile	All	0.935	0.709	.006	22	view →
LUAD	OS	Tertile	III,IV	0.839	0.328	.026	10	view →
PDAC	OS	Quartile	All	0.996	0.886	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PRPF4B–HNSC (DFS)

Open the HNSC breakdown →